- Home
- COTY vs EXAS Comparison
COTY vs EXAS Comparison
Compare COTY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COTY
- EXAS
- Stock Information
- Founded
- COTY 1904
- EXAS 1995
- Country
- COTY United States
- EXAS United States
- Employees
- COTY N/A
- EXAS N/A
- Industry
- COTY Package Goods/Cosmetics
- EXAS Medical Specialities
- Sector
- COTY Consumer Discretionary
- EXAS Health Care
- Exchange
- COTY Nasdaq
- EXAS Nasdaq
- Market Cap
- COTY N/A
- EXAS 12.3B
- IPO Year
- COTY 2013
- EXAS N/A
- Fundamental
- Price
- COTY $7.78
- EXAS $71.05
- Analyst Decision
- COTY Buy
- EXAS Strong Buy
- Analyst Count
- COTY 14
- EXAS 13
- Target Price
- COTY $11.82
- EXAS $79.00
- AVG Volume (30 Days)
- COTY 5.3M
- EXAS 1.4M
- Earning Date
- COTY 11-06-2024
- EXAS 11-05-2024
- Dividend Yield
- COTY N/A
- EXAS N/A
- EPS Growth
- COTY N/A
- EXAS N/A
- EPS
- COTY 0.09
- EXAS N/A
- Revenue
- COTY $6,118,000,000.00
- EXAS $2,612,011,000.00
- Revenue This Year
- COTY $7.62
- EXAS $15.53
- Revenue Next Year
- COTY $6.21
- EXAS $13.78
- P/E Ratio
- COTY $88.93
- EXAS N/A
- Revenue Growth
- COTY 10.15
- EXAS 13.54
- 52 Week Low
- COTY $7.35
- EXAS $40.62
- 52 Week High
- COTY $13.30
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- COTY 35.92
- EXAS 55.81
- Support Level
- COTY $7.52
- EXAS $68.61
- Resistance Level
- COTY $7.71
- EXAS $71.49
- Average True Range (ATR)
- COTY 0.25
- EXAS 1.91
- MACD
- COTY -0.02
- EXAS -0.34
- Stochastic Oscillator
- COTY 23.04
- EXAS 50.41
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.